By Marie Rosenthal, MS
The CDC’s Advisory Committee on Immunization Practices (ACIP) recommended the use of meningococcal groups A, B, C, W and Y vaccine (MenABCWY; Penmenvy, GSK) as part of the adolescent meningococcal vaccination schedule to protect against disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y).
On Feb. 14, the FDA approved GSK’s MenABCWY vaccine, which combines the antigenic components of the company’s two meningococcal vaccines: Bexsero